Agilent Technologies, a leading maker of laboratory instruments, disclosed on Tuesday that it will acquire Proscia, a privately held developer of digital pathology software, for $240 million in cash with an additional up to $30 million tied to future performance targets. The transaction, expected to close early in Agilent’s fiscal 2027, deepens the company’s push into artificial‑intelligence‑enabled diagnostics.
Why the acquisition matters
Proscia’s platform converts traditional pathology slides into digital images that can be stored, reviewed, and analyzed using AI tools. By integrating this capability, Agilent aims to strengthen its pathology business and broaden its presence in the fast‑growing market for digital and AI‑driven diagnostic solutions. The software business generated more than $18 million in revenue over the past twelve months, indicating a solid base for future expansion.
Building on an existing partnership
The two companies have collaborated since 2022 under a multi‑year distribution agreement that combined Agilent’s pathology hardware with Proscia’s software to offer a complete digital pathology system. This longstanding partnership laid the groundwork for the acquisition, allowing Agilent to bring the software in‑house and accelerate product development.
Strategic benefits for Agilent
Agilent’s leadership highlighted several strategic advantages:
- Expanded product portfolio: Adding Proscia’s software gives Agilent a full‑stack solution from sample preparation to AI‑driven analysis.
- Access to a high‑growth market: Digital pathology and AI diagnostics are projected to grow rapidly as hospitals and research labs seek faster, more accurate results.
- Revenue diversification: The software business provides recurring revenue streams that complement Agilent’s traditional instrument sales.
Company officials expect the acquisition to create cross‑selling opportunities and enhance Agilent’s competitive position against other major laboratory‑equipment manufacturers that are also investing in AI technologies.
Financial terms and timeline
The deal consists of a $240 million cash payment at closing, with an earn‑out component of up to $30 million contingent on Proscia meeting specified performance milestones after the acquisition. The transaction is slated to close early in Agilent’s fiscal year 2027, subject to customary closing conditions and regulatory approvals.
Industry context
The move reflects a broader industry trend toward integrating AI into diagnostic workflows. Hospitals are increasingly adopting digital pathology to improve turnaround times, reduce errors, and enable remote consultations. By securing a proven software platform, Agilent positions itself to meet the rising demand for intelligent diagnostic tools.
Outlook
Analysts note that the acquisition could accelerate Agilent’s revenue growth in the diagnostics segment, which has been a focus of the company’s recent strategic initiatives. While the exact financial impact will depend on how quickly the combined solutions gain market traction, the partnership’s existing customer base and the growing appetite for AI‑driven pathology suggest a positive trajectory.
Overall, Agilent’s purchase of Proscia underscores the company’s commitment to advancing cutting‑edge diagnostic technology and delivering value to laboratories, clinicians, and patients across the United States and beyond.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
